Disease characteristics and patient-reported outcomes of all patients with PsA at time of enrolment
| All patients | Patients with PsA categorised by skin and joint activity | P value | ||||||
| 0% | >0% to 3% | >3% | ||||||
| Low | M/H | Low | M/H | Low | M/H | |||
| Enthesitis, n n (%) with SPARCC score >0 | 1542 282 (18.3) | 258 22 (8.5) | 109 23 (21.1) | 447 61 (13.7) | 227 79 (34.9) | 256 18 (7.0) | 245 79 (32.2) | <0.001 |
| SPARCC score (among those with enthesitis) | 0.0003 | |||||||
| Mean (SD) | 4.1±3.1 | 2.9±2.1 | 5.3±3.1 | 3.0±2.3 | 4.4±2.8 | 3.9±2.5 | 4.8±3.8 | |
| Median (IQR) | 3.0 (2.0, 6.0) | 2.0 (1.0, 4.0) | 6.0 (3.0, 7.0) | 2.0 (1.0, 4.0) | 4.0 (2.0, 7.0) | 3.5 (2.0, 6.0) | 4.0 (2.0, 7.0) | |
| Dactylitis, n | 1542 | 258 | 109 | 447 | 227 | 256 | 245 | <0.001 |
| n (%) with dactylitis count >0 | 141 (9.1) | 8 (3.1) | 10 (9.2) | 27 (6.0) | 39 (17.2) | 8 (3.1) | 49 (20.0) | |
| Dactylitis count (among those with dactylitis) | ||||||||
| Mean (SD) | 2.2±1.8 | 1.4±0.7 | 2.4±1.8 | 1.6±1.3 | 2.4±2.0 | 1.1±0.4 | 2.7±1.8 | 0.018 |
| Median (IQR) | 2.0 (1.0, 3.0) | 1.0 (1.0, 1.5) | 1.5 (1.0, 4.0) | 1.0 (1.0, 2.0) | 2.0 (1.0, 3.0) | 1.0 (1.0, 1.0) | 2.0 (2.0, 4.0) | |
| MDA, n | 1426 | 245 | 103 | 416 | 203 | 238 | 221 | <0.001 |
| n (%) | 639 (44.8) | 180 (73.5) | 22 (21.4) | 296 (71.2) | 33 (16.3) | 102 (42.9) | 6 (2.7) | |
| Clinical global assessment of psoriasis, n | 1523 | 255 | 107 | 440 | 225 | 255 | 241 | |
| Clear, n (% of N) | 380 (25.0) | 242 (94.9) | 95 (88.8) | 21 (4.8) | 14 (6.2) | 7 (2.8) | 1 (0.4) | <0.001 |
| Almost clear, n (% of N) | 540 (35.5) | 13 (5.1) | 8 (7.5) | 298 (67.7) | 118 (52.4) | 61 (23.9) | 42 (17.4) | <0.001 |
| Mild disease, n (% of N) | 372 (24.4) | 0 (0.0) | 4 (3.7) | 99 (22.5) | 76 (33.8) | 101 (39.6) | 92 (38.2) | <0.001 |
| Moderate disease, n (% of N) | 200 (13.1) | 0 (0.0) | 0 (0.0) | 22 (5.0) | 17 (7.6) | 75 (29.4) | 86 (35.7) | <0.001 |
| Severe disease, n (% of N) | 31 (2.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 11 (4.3) | 20 (8.3) | <0.001 |
| BSA (%), n | 1542 | 258 | 109 | 447 | 227 | 256 | 245 | <0.001 |
| Mean (SD) | 5.6±11.2 | 0.0±0.0 | 0.0±0.0 | 1.6±0.7 | 1.6±0.8 | 14.4±14.8 | 16.2±16.6 | |
| Median (IQR) | 2.0 (1.0, 5.0) | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.0) | 1.0 (1.0, 2.0) | 1.0 (1.0, 2.0) | 9.0 (6.0, 16.0) | 10.0 (5.0, 18.0) | |
| CDAI, n | 1542 | 258 | 109 | 447 | 227 | 256 | 245 | <0.001 |
| Mean (SD) | 10.4±9.3 | 4.7±3.3 | 18.6±8.9 | 5.0±3.2 | 18.3±8.2 | 5.4±3.0 | 20.5±10.0 | |
| Median (IQR) | 8.5 (3.5, 14.0) | 4.4 (1.7, 8.0) | 15.5 (12.0, 21.0) | 4.8 (2.0, 8.0) | 16.0 (12.5, 22.0) | 5.5 (3.0, 8.0) | 17.7 (13.5, 24.5) | |
| DAS28-CRP, n | 856 | 165 | 73 | 230 | 122 | 135 | 131 | <0.001 |
| Mean (SD) | 2.6±1.1 | 1.8±0.6 | 3.5±0.9 | 2.0±0.6 | 3.7±0.9 | 2.0±0.6 | 3.9±0.9 | |
| Median (IQR) | 2.4 (1.8, 3.3) | 1.8 (1.3, 2.3) | 3.4 (3.0, 4.1) | 2.0 (1.6, 2.5) | 3.5 (3.1, 4.1) | 2.0 (1.6, 2.4) | 3.8 (3.1, 4.4) | |
| DAS28-CRP, n | 856 | 165 | 73 | 230 | 122 | 135 | 131 | <0.001 |
| Low, n (% of N) | 496 (57.9) | 156 (94.6) | 13 (17.8) | 193 (83.9) | 11 (9.0) | 117 (86.7) | 6 (4.6) | <0.001 |
| Moderate, n (% of N) | 260 (30.4) | 9 (5.6) | 42 (57.5) | 37 (16.1) | 78 (63.9) | 18 (13.3) | 76 (58.0) | <0.001 |
| High, n (% of N) | 100 (11.7) | 0 (0.0) | 18 (24.7) | 0 (0.0) | 22 (27.1) | 0 (0.00) | 49 (37.4) | <0.001 |
| Nail involvement, n (%) | 677 (43.9) | 66 (25.6) | 36 (33.0) | 174 (38.9) | 115 (50.7) | 127 (49.6) | 159 (64.9) | <0.001 |
| Nail PsO VAS (among those with nail involvement) (0–100): mean (SD) | 16.2±21.6 | 9.9±10.3 | 19.0±50.1 | 10.7±13.1 | 13.5±14.2 | 16.6±20.0 | 25.8±24.3 | <0.001 |
| Median (IQR) | 8.0 (4.0, 20.0) | 5.0 (3.0, 15.0) | 5.0 (3.0, 15.0) | 5.0 (3.0, 13.0) | 7.0 (4.0, 20.0) | 7.0 (4.0, 21.0) | 20.0 (5.0, 40.0) | |
| HAQ (0–3), n | 1448 | 248 | 105 | 420 | 209 | 241 | 225 | <0.001 |
| Mean (SD) | 0.61±0.6 | 0.38±0.5 | 0.88±0.7 | 0.40±0.5 | 0.87±0.7 | 0.45±0.5 | 1.06±0.7 | |
| Median (IQR) | 0.38 (0.0, 1.0) | 0.13 (0.0, 0.6) | 0.75 (0.3, 1.5) | 0.25 (0.0, 0.6) | 0.88 (0.4, 1.4) | 0.25 (0.0, 0.8) | 1.00 (0.5, 1.5) | |
| Patient pain VAS (0–100), n | 1438 | 247 | 104 | 418 | 208 | 239 | 222 | <0.001 |
| Mean (SD) | 37.6±29.3 | 26.7±26.0 | 45.9±28.9 | 28.1±25.9 | 50.0±26.6 | 32.7±28.2 | 57.1±27.6 | |
| Median (IQR) | 30.0 (10.0, 65.0) | 20.0 (5.0, 43.0) | 48.0 (17.5, 70.0) | 20.0 (5.0, 50.0) | 50.0 (30.0, 71.5) | 25.0 (10.0, 50.0) | 60.0 (35.0, 80.0) | |
| EQ5D (0–1), n | 1516 | 254 | 105 | 440 | 225 | 253 | 239 | <0.001 |
| Mean (SD) | 72.3±21.1 | 79.4±18.9 | 64.3±23.8 | 77.9±17.5 | 66.5±20.7 | 76.9±16.9 | 58.8±23.4 | |
| Median (IQR) | 80.0 (60.0, 90.0) | 85.0 (73.0, 92.0) | 70.0 (50.0, 80.0) | 80.0 (70.0, 90.0) | 70.0 (50.0, 81.0) | 80.0 (70.0, 90.0) | 60.0 (40.0, 80.0) | |
| Patient-reported fatigue (0–100), n | 1517 | 255 | 107 | 438 | 223 | 250 | 244 | <0.001 |
| Mean (SD) | 40.2±29.1 | 31.4±27.2 | 45.2±29.4 | 33.3±27.1 | 49.7±27.8 | 37.4±29.1 | 54.0±28.2 | |
| Median (IQR) | 40.0 (12.0, 65.0) | 25.0 (8.0, 55.0) | 45.0 (20.0, 70.0) | 25.0 (10.0, 55.0) | 50.0 (25.0, 75.0) | 30.0 (10.0, 63.0) | 60.0 (31.0, 75.0) | |
| Morning stiffness, n | 1489 | 251 | 104 | 429 | 222 | 241 | 242 | <0.001 |
| 0 hour, n (%) | 172 (11.6) | 46 (18.3) | 5 (4.8) | 67 (15.6) | 13 (5.9) | 32 (13.3) | 9 (3.7) | |
P value represents comparisons between CDAI/BSA subgroups and were analysed using χ2 tests, Fisher’s exact tests, t-tests or Wilcoxon-Mann-Whitney tests, as appropriate. Skin severity by levels of BSA: 0%, >0% to 3% and >3%; joint activity by levels of CDAI: low and M/H.
BSA, body surface area; CDAI, Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score 28-joint count C-reactive protein; EQ5D, EuroQol Group 5-Dimensional Questionnaire; HAQ, Health Assessment Questionnaire; MDA, mild disease activity; M/H, moderate/high; PsA, psoriatic arthritis; SPARCC, Spondyloarthritis Research Consortium of Canada; VAS, visual analogue scale.